nach oben

memo - Magazine of European Medical Oncology

Erschienen in:

25.05.2020 | original report

Comparison of outcomes of two non-BCNU-containing conditioning regimens used in autologous stem cell transplantation for relapsed/refractory lymphoma

verfasst von: Amro Mohamed Sedky El-Ghammaz, Maha El-Zimaity, Afaf Abdel-Aziz Abdel-Ghaffar

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 3/2020

Einloggen, um Zugang zu erhalten

Summary

Background

A comparison was performed of outcomes of two non-BCNU-containing conditioning regimens used in autologous stem cell transplantation (ASCT) for lymphoma due to the lack of superiority of any regimen over others in the setting of the global BCNU shortage.

Methods

CCVP-16 and LEAM conditioning regimens were compared in 55 relapsed/refractory lymphoma patients regarding engraftment timing, hospitalization duration, toxicity profile, disease progression and survival.

Results

There was insignificant difference between the two regimens regarding engraftment timings, hospitalization durations and toxicities. However, LEAM was associated with a lower post-ASCT disease progression rate than CCVP-16 in the whole cohort and in the Hodgkin lymphoma subgroup. Overall survival did not differ between the two regimens in the whole cohort and in Hodgkin lymphoma and diffuse large B cell lymphoma subgroups. In contrast, progression free survival was superior with LEAM in comparison to CCVP-16 in the whole cohort and in the Hodgkin lymphoma subgroup.

Conclusion

LEAM is more effective than CCVP-16 in ASCT for lymphoma, especially Hodgkin lymphoma, and has a comparable toxicity profile.

Vorheriger Artikel Patient-reported outcomes and psycho-oncological screening in hematology: a practical example of routine electronic monitoring

Nächster Artikel Adjuvant and neoadjuvant treatment of melanoma

Filmont JE, Gisselbrecht C, Cuenca X, et al. The impact of pre- and post-transplantation positron emission tomography using 18-fluorodeoxyglucose on poor-prognosis lymphoma patients undergoing autologous stem cell transplantation. Cancer. 2007;110:1361–9.CrossRef

Armitage JO. Treatment of non-Hodgkin’s lymphoma. N Engl J Med. 1993;328:1023–30.CrossRef

Colpo A, Hochberg E, Chen YB. Current status of autologous stem cell transplantation in relapsed and refractory Hodgkin’s lymphoma. Oncologist. 2012;17:80–90.CrossRef

Nademanee A. Transplantation for non-Hodgkin lymphoma. Expert Rev Hematol. 2009;2:425–42.CrossRef

Rezvani AR, Storb RF. Separation of graft-vs.-tumor effects from graft-vs.-host disease in allogeneic hematopoietic cell transplantation. J Autoimmun. 2008;30(3):172–9.CrossRef

Mounier N, Gisselbrecht C. Conditioning regimens before transplantation in patients with aggressive non-Hodgkin’s lymphoma. Ann Oncol. 1998;9(Suppl. I):S15–S21.CrossRef

Sharma A, Kayal S, Iqbal S, Malik PS, Raina V. Comparison of BEAM vs. LEAM regimen in autologous transplant for lymphoma at AIIMS. SpringerPlus. 2013;2:489.CrossRef

Stuart MJ, Chao NS, Horning SJ, et al. Efficacy and toxicity of a CCNU-containing high-dose chemotherapy regimen followed by autologous hematopoietic cell transplantation in relapsed or refractory Hodgkin’s disease. Biol Blood Marrow Transplant. 2001;7:552–60.CrossRef

Fernandez HF, Escalon MP, Pereira D, Lazarus HM. Autotransplant conditioning regimens for aggressive lymphoma: are we on the right road? Bone Marrow Transplant. 2007;40:505–13.CrossRef

10.

Sorror ML, Maris MB, Storb R, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106:2912–9.CrossRef

11.

Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32:3059–67.CrossRef

12.

Mabed M, Shamaa S. High-dose chemotherapy plus non-cryopreserved autologous peripheral blood stem cell transplantation rescue for patients with refractory or relapsed Hodgkin disease. Biol Blood Marrow Transplant. 2006;12:942–8.CrossRef

13.

Ramzi M, Mohamadian M, Vojdani R, et al. Autologous non-cryopreserved hematopoietic stem cell transplant with CEAM as a modified conditioning regimen in patients with Hodgkin lymphoma: a single-center experience with a new protocol. Exp Clin Transplant. 2012;2:163–7.CrossRef

14.

U.S. Department of Health and Human Services. Common terminology criteria for adverse events (CTCAE) version 5.0. National institutes of health, national cancer institute. 2017. https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5 × 11.pdf. Accessed 10 Feb 2018.

15.

Salar A, Sierra J, Gandarillas M, et al. Autologous stem cell transplantation for clinically aggressive non-Hodgkin’s lymphoma: the role of preparative regimens. Bone Marrow Transplant. 2001;27(4):405–12.CrossRef

16.

Majhail NS, Ness KK, Burns LJ, et al. Late effects in survivors of Hodgkin and non-Hodgkin lymphoma treated with autologous hematopoietic cell transplantation: a report from the bone marrow transplant survivor study. Biol Blood Marrow Transplant. 2007;13:1153–9.CrossRef

17.

Gutierrez-Delgado F, Maloney DG, Press OW, et al. Autologous stem cell transplantation for non-Hodgkin’s lymphoma: comparison of radiation-based and chemotherapy-only preparative regimens. Bone Marrow Transplant. 2001;28:455–61.CrossRef

18.

Caballero MD, Rubio V, Rifon J, et al. BEAM chemotherapy followed by autologous stem cell support in lymphoma patients: analysis of efficacy, toxicity and prognostic factors. Bone Marrow Transplant. 1997;20:451–8.CrossRef

19.

Alessandrino EP, Bernasconi P, Colombo A, et al. Pulmonary toxicity following carmustine-based preparative regimens and autologous peripheral blood progenitor cell transplantation in hematological malignancies. Bone Marrow Transplant. 2000;25:309–13.CrossRef

20.

Cordonnier C, Vernant JP, Mital P, Lange F, Bernaudin JF, Rochant H. Pulmonary fibrosis subsequent to high doses of CCNU for chronic myeloid leukemia. Cancer. 1983;51:1814–8.CrossRef

21.

Charley C, Babic A, Bargalló Arraut I, Ferrero I. JACIE and quality management in HSCT: implications for nursing. In: Kenyon M, Babic A, editors. The European blood and marrow transplantation textbook for nurses. Cham: Springer; 2018. pp. 1–22.

22.

Chen YB, Lane AA, Logan B, et al. Impact of conditioning regimen on outcomes for patients with lymphoma undergoing high-dose therapy with autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2015;21(6):1046–53.CrossRef

23.

Gupta A, Gokarn A, Rajamanickam D, et al. Lomustine, cytarabine, cyclophosphamide, etoposide—an effective conditioning regimen in autologous hematopoietic stem cell transplant for primary refractory or relapsed lymphoma: Analysis of toxicity, long-term outcome, and prognostic factors. J Cancer Res Ther. 2018;14(5):926–33.CrossRef

24.

Zhang J, Grubor V, Love CL, et al. Genetic heterogeneity of diffuse large B‑cell lymphoma. Proc Natl Acad Sci U S A. 2013;110(4):1398–403.CrossRef

25.

Shu Z, Heimfeld S, Gao D. Hematopoietic stem cell transplantation with cryopreserved grafts: adverse reactions after transplantation and cryoprotectant removal prior to infusion. Bone Marrow Transplant. 2014;49:469–76.CrossRef

Titel: Comparison of outcomes of two non-BCNU-containing conditioning regimens used in autologous stem cell transplantation for relapsed/refractory lymphoma
verfasst von: Amro Mohamed Sedky El-Ghammaz
Maha El-Zimaity
Afaf Abdel-Aziz Abdel-Ghaffar
Publikationsdatum: 25.05.2020
Verlag: Springer Vienna
Erschienen in: memo - Magazine of European Medical Oncology / Ausgabe 3/2020
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI: https://doi.org/10.1007/s12254-020-00621-0

Springer Medizin Österreich

Summary

Background

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2020

The therapeutic landscape of advanced melanoma

Adjuvant and neoadjuvant treatment of melanoma

Creating the “new normal” post-Coronavirus world—web-communication replacing face-to-face interaction

Managing an oncology clinic during the COVID-19 pandemic—how we did it in Sarajevo?

Four lines of immunochemotherapy combinations in a young patient with an aggressive metastatic colorectal cancer

Highlights of ASH 2019—multiple myeloma